logo
Endo Champions Men's Health Month with Education, Awareness, and Outreach

Endo Champions Men's Health Month with Education, Awareness, and Outreach

MALVERN, Pa., June 2, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health and addressing health issues affecting men.
Throughout the month of June, Endo is spearheading a range of activities designed to empower men to take charge of their physical, mental, and sexual health. The effort also aims to raise awareness among healthcare providers and patients about commonly underdiagnosed and stigmatized conditions such as Peyronie's disease, erectile dysfunction and testosterone deficiency.
Key components of the campaign include:
'Men may not always be the strongest advocates for their own health, but with the right information and awareness, we can empower them to take a more active role in their well-being,' said Justin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. 'At Endo, we offer a unique portfolio of men's health products and equip healthcare providers with tools and education so they can support their patients in their health journey.'
In support of the national effort, Endo will also participate in Wear Blue Day on June 13, a symbolic initiative encouraging individuals and organizations to wear blue to raise awareness of men's health issues.
For more information about Endo's initiatives and resources for Men's Health Month, visit the men's health section of endo.com.
About Men's Health Month
Men's Health Month is observed every June to raise awareness about health issues that specifically affect men. The initiative emphasizes the importance of early detection, preventive care, and effective treatment, encouraging men to take proactive steps toward managing their overall health and well-being.
About Endo
Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Mattice and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plan,' 'will,' 'may,' 'look forward,' 'intends,' 'guidance,' 'future,' 'potential' or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading 'Risk Factors' in Endo's most recent Form 10-K and Form 10-Q.
View original content to download multimedia: https://www.prnewswire.com/news-releases/endo-champions-mens-health-month-with-education-awareness-and-outreach-302469557.html
SOURCE Endo, Inc.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Green Hydrogen Production Group Closes on Major Investment
Green Hydrogen Production Group Closes on Major Investment

Yahoo

time16 minutes ago

  • Yahoo

Green Hydrogen Production Group Closes on Major Investment

A California-based hydrogen production group said it has completed a funding round in support of the company's first 100-kilotonne carbon dioxide removal (CDR) commercial facility. Equatic, which is considered a pioneering company in combined carbon dioxide removal and green hydrogen production, on August 11 announced the successful closure of its Series A round, with Catalytic Capital for Climate and Health (C3H) leading an $11.6-million investment. C3H is a catalytic vehicle by Temasek Trust, along with Kibo Invest, a Singapore-based private investment office with a focus on climate technology. The funding round, with participation from a consortium of global investors, will accelerate the engineering scale-up and commercialization of Equatic's patented seawater electrolysis technology. This substantial capital infusion will support the ongoing engineering of Equatic's CDR commercial facility, alongside further commercialization, manufacturing, and technological development. Equatic's proprietary technology is designed to capture atmospheric carbon dioxide and produce green hydrogen in a single, scalable process, advancing two critical net-zero pathways. 'This investment marks a pivotal moment for Equatic, enabling us to significantly scale our production capabilities and accelerate our mission to deliver durable carbon removal at scale,' said Gaurav N. Sant, founder and chief technology officer for Equatic. 'The Temasek Trust ecosystem has been a foundational partner to Equatic, from early-stage philanthropic backing from Temasek Foundation to catalytic investment through C3H. We welcome Kibo Invest as co-lead and recognize their commitment to invest in companies that are revolutionizing industries and addressing urgent climate challenges.' 'Truly innovative carbon management technologies are needed to mitigate climate change before the consequences become irreversible,' said Lord John Browne, chairman of Equatic's advisory board. Browne also is founder and chairman at BeyondNetZero, and the former CEO of British Petroleum. 'By removing carbon dioxide and simultaneously generating green hydrogen, Equatic's solution provides unique advantages in terms of cost and scalability.' Ryan Tan, head of C3H, said, 'Equatic's technology and approach exemplify the type of bold and scalable innovation that aligns with C3H's mandate. We are delighted to support Equatic's goal in advancing promising climate mitigation solutions that offer permanent, durable carbon removal with green hydrogen production for scalable, tangible impact and commercial benefit.' 'Equatic represents an exciting opportunity to scale deep-tech innovation that addresses two critical needs: decarbonisation and clean energy. As an investor focused on climate solutions, we are proud to partner with C3H and Equatic to help bring this breakthrough technology to commercial scale,' said James Marshall, CEO of Kibo Invest. Equatic's Technology Since commencing operations in 2023, the Equatic technology has been successfully deployed at two pilot plants in Los Angeles and Singapore. The company is now expanding its operations with a demonstration plant in Singapore, known as Equatic-1, and a commercial-scale plant in Canada. In May 2024, Equatic was recognized as a CDR Purchase Prize semifinalist by the U.S. Department of Energy, acknowledging its high-quality, permanent carbon credits and rigorous Monitoring, Reporting, and Verification (MRV) practices. In September 2024, Equatic announced a significant climate breakthrough with the U.S. manufacture of oxygen-selective anodes, which unlock scalable hydrogen production through direct seawater electrolysis. That same month, Equatic was named a finalist for The Earthshot Prize, a prestigious international recognition for groundbreaking solutions to repair the planet. Equatic's commitment to high-integrity carbon removal is underscored by its adoption of an ISO-14064 standard for MRV, first published by Equatic in May 2023. Subsequently, this standard was validated by two leading carbon removal registries, Isometric and making Equatic one of the only marine companies capable of issuing high-quality CDR credits under either registry, with full transparency and auditability. Buyers of Equatic's CDR credits include Boeing, a leading global aerospace company and other large industrial companies committed to market-based mechanisms for decarbonization. —POWER edited this content, which was contained in a press release from Equatic.

Mizuho Lowers PT on Acadia Healthcare Company (ACHC) to $22 From $32, Keeps a Neutral Rating
Mizuho Lowers PT on Acadia Healthcare Company (ACHC) to $22 From $32, Keeps a Neutral Rating

Yahoo

time21 minutes ago

  • Yahoo

Mizuho Lowers PT on Acadia Healthcare Company (ACHC) to $22 From $32, Keeps a Neutral Rating

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the top cheap stocks that will go to the moon according to Reddit. On August 14, Mizuho analyst Ann Hynes lowered the firm's price target on Acadia Healthcare Company, Inc. (NASDAQ:ACHC) to $22 from $32, keeping a Neutral rating on the shares. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. The rating update came after Acadia Healthcare Company, Inc. (NASDAQ:ACHC) reported fiscal Q2 results that missed consensus estimates when excluding the incremental effect of direct provider payments in the quarter. The firm slashed its 2025-2027 adjusted EBITDA estimates and is staying on the sidelines, attributing the stance to 'execution missteps' and uncertainty regarding the effects of the ongoing Medicaid Redeterminations and the One Big Beautiful Bill Act. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US in various settings, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Bernstein Reiterates a Buy Rating on Charter Communications (CHTR), Sets a $380 PT
Bernstein Reiterates a Buy Rating on Charter Communications (CHTR), Sets a $380 PT

Yahoo

time21 minutes ago

  • Yahoo

Bernstein Reiterates a Buy Rating on Charter Communications (CHTR), Sets a $380 PT

Charter Communications, Inc. (NASDAQ:CHTR) is one of the top cheap stocks that will go to the moon according to Reddit. In a report released on August 12, Laurent Yoon from Bernstein reiterated a Buy rating on Charter Communications, Inc. (NASDAQ:CHTR), setting a price target of $380.00. A line of cable boxes and modern televisions, representing the company's video services. Charter Communications, Inc. (NASDAQ:CHTR) reported its fiscal Q2 results on July 25, with total Internet customers decreasing by 117,000. Total mobile lines for the quarter rose by 500,000. As of June 30, Charter Communications, Inc. (NASDAQ:CHTR) serves 29.9 million Internet customers, 10.9 million mobile lines, and 31.2 million customer relationships (excluding mobile-only relationships). Charter Communications, Inc. (NASDAQ:CHTR) also reported that revenue for Q2 rose 0.6% year-over-year to $13.8 billion, supported by residential mobile service revenue growth of 24.9%, residential Internet revenue growth of 2.8%, and other revenue growth of 18.9%. Charter Communications, Inc. (NASDAQ:CHTR) provides broadband communications services. The company's offerings include Spectrum TV, Spectrum Internet, and Spectrum Voice. Charter Communications, Inc. (NASDAQ:CHTR) also offers data networking, business-to-business Internet access, video and music entertainment services, business telephone, and wireless backhaul. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store